Homocysteine: Exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy

Pharmacogenomics

Volumn 5, Issue 8, 2004, Pages 1151-1162

  Valik, Dalibor ^a   Radina, Martin ^b   Sterba, Jaroslav ^c   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b J G Mendel Cancer Center   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Biomarker; Homocysteine; Methotrexate; Pharmacogenetics

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; BIOLOGICAL MARKER; COBALAMIN; CYANOCOBALAMIN; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; FOLINIC ACID; HOMOCYSTEINE; METHOTREXATE; PYRIDOXINE; SULFUR AMINO ACID; THYMIDYLATE SYNTHASE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; EUKARYOTIC CELL; FOLATE METABOLISM; GRANULOCYTOPENIA; HUMAN; LIVER TOXICITY; METABOLIC DISORDER; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PHARMACODYNAMICS; PHARMACOGENETICS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN METABOLISM;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; FOLIC ACID ANTAGONISTS; HOMOCYSTEINE; HUMANS; METHOTREXATE; NEOPLASMS;

EUKARYOTA;

EID: 11044223935     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.8.1151     Document Type: Article

References (75)

1. Mudd HS, Levy HL, Kraus JP: Disorders of transsulfuration. In: The Metabolic and Molecular Bases of Inherited Disease (Vol. 2, 8th edn). Scriver C (Ed.), McGraw-Hill 2007-2056 (2001).
2. Refsum H, David Smith A, Ueland PM et al.: Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem. 50, 3-32 (2004).
3. Mudd HS: Biochemical mechanism in methyl group transfer. In: Metabolic Conjugation and Metabolic Hydrolysis (Vol. 3). Fishman WH (Ed.), New York Academic, USA 297 (1973).
4. Lundberg P, Dudman NPB, Kuchel PW, Wilcken DEL: NMR determination of urinary betaine in patients with premature vascular disease and mild hyperhomocysteinemia. Clin. Chem. 41, 275 (1995).
5. Taylor RT, Weissbach H: N5-methyltetrahydrofolate-homocysteine methyltransferases. In: The Enzymes: Part B (Vol. 9, 3rd edn). Boyer PD (Ed.), New York Academic, USA 121 (1973).
6. Mudd SH, Levy HL: Plasma homocyst(e)ine or homocysteine? N. Eng. J. Med. 333, 325 (1995).
7. Huijgen HJ, Tegelaers FP, Schoenmakers CH, Pronk-Admiraal CJ, Ekema S: Multicenter analytical evaluation of an enzymatic method for the measurement of plasma homocysteine and comparison with HPLC and immunochemistry. Clin. Chem. 50(5), 937-941 (2004).
8. Jakubowski H: Molecular basis of homocysteine toxicity in humans. Cell Mol. Life Sci. 61(4), 470-487 (2004).
9. Wilcken DEL, Wilcken B: The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J. Clin. Invest. 57, 1079-1082 (1976).
10. Graham IM, Daly LE, Refsum HM et al.: Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 277, 1775-1781 (1997).
11. Brattström LE, Wilcken DEL, Ohrvik J, Brudin L: Common methylene tetrahydrofolate reductase gene mutation lead to hyperhomocysteinemia but not to vascular disease: the result of metaanalysis. Circulation 98, 2520-2526 (1998).
12. Jakubowski H: Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J. Biol. Chem. 277(34), 30425-30428 (2002).
13. Blakley RL Benkovic SJ: Folates and Pterins. Chemistry and Biochemistry of Folates. John Wiley, New York (1984).
14. Rosenblatt DS: Inherited disorders of folate transport and metabolism. In: The Metabolic and Molecular Basis of Inherited Disease Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 3111 (1995).
15. Fairbanks VF, Klee GG: Biochemical aspects of hematology. In: Tietz Textbook of Clinical Chemistry (3rd edn). Burris CA, Ashwood RA (Eds), WB Saunders Company, Philadelphia, USA 1690-1698 (1999).
16. Moscow JA, Gong M, He R et al.: Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient methotrexate-resistant human breast cancer cells. Cancer Res. 55, 3790 (1995).
17. Wang H, Ross JF, Ratnam M: Structure and regulation of a polymorphic gene encoding folate receptor type γ/γ. Nucleic Acid Res. 26, 2132 (1998).
18. Taylor SM, Freemantle SJ, Moran RG: Structural organization of the human folylpoly-γ-glutamate synthetase gene; evidence for a single genomic locus. Cancer Res. 55, 6030 (1995).
19. Hoffbrand AV, Tripp E, Lavoie A: Synthesis of folate polyglutamates in human cells. Clin. Sci. Mol. Med. 50, 61-68 (1976).
20. Farber S, Diamond LK, Mercer RD et al.: Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N. Engl. J. Med. 238, 787-793 (1948).
21. United States Pharmacopoeia Dispensing Information (USP DI). Drug reference guide, Micromedex (19th edn.) 1962-1969 (1999).
22. Zhao R, Goldman ID: Resistance to antifolates. Oncogene 22, 7431-7457 (2003).
23. Schrappe M: Evolution of BFM trials for childhood ALL. Ann. Hematol. 83(Suppl. 1), S121-S123 (2004).
24. Whittle SL, Hughes RA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 3, 267-271 (2004).
25. Siveke JT, Folwaczny C: Medical approaches and future option in chronic active ulcerative colitis. Int. J. Colorectal Dis. 19(4), 297-307 (2004).
26. Principles and Practice of Pediatric Oncology (3rd edn) Pizzo PA, Poplack DG (Eds), Lippincott-Raven Publishers 237-240 (1997).
27. Genestier L, Paillot R, Quemeneur L et al.: Mechanism of action of methotrexate. Immunopharmacology 47, 247-257 (2000).
28. Jolivet J, Cowan KH, Curt GA: The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309, 1094-1104 (1983).
29. Winter-Vann AM, Kamen BA, Bergo MO et al.: Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc. Natl. Acad. Sci. USA 100(11), 6529-6534 (2003).
30. Chiang PK, Gordon RK, Tal J et al.: S Adenosylmethionine and methylation. FASEB J. 4, 471-480 (1996).
31. Kobayashi K, Terada C, Tsukamoto I: Methotrexate-induced apoptosis in hepatocytes after partial hepatectomy. Eur. J. Pharmacol. 438, 19-24 (2002).
32. Paillot R, Genestier S, Foumel S et al.: Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc. 30, 2348-2350 (1998).
33. Chern CL, Huang RFS, Chen YH et al.: Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-κB in human Hep G2 cells. Biomed. Pharmacother. 55, 434-442 (2001).
34. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408 (6810), 307-310 (2000).
35. Van Triest B, Pinedo HM, Giaccone G, Peters GJ: Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann. Oncol. 11 (4), 385-391 (2000).
36. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochem. Biophys. Acta 1587(2-3), 164-173 (2002).
37. Blount BC, Mack MM, Wehr CM et al.: Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implication of cancer and neuronal damage. Proc. Natl. Acad. Sci. USA 94, 3290-3295 (1997).
38. Duthie SJ, Narayanan Y, Blum S, Pirie L, Brand GM: Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr. Cancer 37, 245-251 (2000).
39. Kishi T, Tanaka Y, Ueda K: Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer 89, 925-931 (2000).
40. Ratain MJ: Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J. Clin. Oncol. 16(7), 2297-2298 (1998).
41. TDM Renaissance and Pharmacogenomic Forum III: Managing the Future. American Association of Clinical Chemistry, Baltimore, USA (2004).
42. Cree IA: Predictive oncology - second conference of the International Society for Chemosensitivity Testing in Oncology. Anticancer Drugs 15(3), 301-302 (2004).
43. Refsum H, Helland S, Ueland PM: Fasting plasma homocysteine as a sensitive indicator of antifolate effect: a study of psoriasis patients receing low-dose methotrexate treatment. Clin. Pharmacol. Ther. 46, 510-520 (1989).
44. Refsum H, Ueland PM, Kvinnsland S: Acute and long-term effect of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res. 46, 5385-5391 (1986).
45. Bronxon EH, Stork LC, Allen RH et al.: Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusion. Cancer Res. 49, 5879-5883 (1989).
46. Goldman ID, Zhao R: Molecular, biochemical and cellular pharmacology of pemetrexed. Semin. Oncol. 29(6, Suppl. 18), 3-17 (2002).
47. Niyikiza C, Baker SD, Setz DE et al.: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 7, 545-552 (2002).
48. 12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc. Am. Soc. Clin. Oncol. 76a, A300 (2001).
49. Peyriere H, Cociglio M, Margueritte G, Vallat C, Blayac JP, Buys D: Optimal management of methotrexate intoxication in a patient with osteosarcoma. Ann. Pharmacother. 38, 422-427 (2004).
50. Pizzo PA, Poplack DG, Bleyer WA: Neurotoxicities of current leukemia therapy. Am. J. Pediatr. Hematol. Oncol. 2, 127-140 (1979).
51. Vezmar S, Becker A, Bode U, Jaehde U: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49, 92-104 (2003).
52. Kishi S, Griener J, Cheng C et al.: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J. Clin. Oncol. 21(16), 3084-3091 (2003).
53. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92, 2675-2682 (1992).
54. Bernini JC, Fort SW, Griener JC et al.: Aminophylline for methotrexate-induced neurotoxicity. Lancet 345, 544-547 (1995 ).
55. 2 intravenous methotrexate. Pediatr. Res. 73, 151-154 (1995).
56. Smith I, Howels DW, Hyland K: Pteridines and monoamines: relevance to neurological damage. Postgrad. Med. J. 62, 113-123 (1986).
57. Phantumchida K, Intragumtorchai T, Kasantikul V: Stroke-like syndrome, mineralizing microangiopathy and neuroaxonal dystrophy following intrathecal methotrexate therapy. Neurology 41, 1847-1848 (1991).
58. Bisschops RH, Van der Graaf Y, Mali WP, Van der Grond J: Elevated levels of plasma homocysteine are associated with neurotoxicity. Atherosclerosis 174, 87-92 (2004).
59. Quinn CT, Griener JC, Bottiglieri T, Arning E, Winick NJ: Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. J. Pediatr. Hematol. Oncol. 26(6), 386-388 (2004).
60. Canal P, Chatelut E, Guichard S: Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 56(6), 1019-1038 (1998).
61. Chabot GG: Factors involved in clinical pharmacology variability in oncology. Rev. Anticancer Res. 14, 2269-2272 (1994 ).
62. Ota J, Yamashita Y, Okawa K et al.: Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncogene 22(36), 5720-5728 (2003).
63. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690-1698 (2002).
64. Matherly LH, Taub JW, Wong SC et al.: Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood 90, 578-589 (1997).
65. Coskun T, Besim A, Ozalp I, Eryilmaz M: Intracranial calcification in dihydropteridine reductase deficiency. Turk. J. Pediatr. 4, 259-264 (1990).
66. Woody RC, Brewster MA, Glasier C: Progressive intracranial calcifications in dihydropterinine reductase deficiency prior to folinic acid therapy. Neurology 5, 673-675 (1989).
67. Lever EG, Elwes RD, Williams A, Reynolds EH: Subacute combined degeneration of the cord due to folate deficiency: response to methylfolate treatment. J. Neurol. Neurosurg. Psychiatry 10, 1203-1207 (1986).
68. Northrup H, Volczik KA: Spina bifida and other neural tube defects. Curr. Problems Pediatr. 10, 313-332 (2000).
69. Vollset SE, Refsum H, Irgens LM et al.: Plasma total homocysteine, pregnancy complications and adverse pregnancy outcomes: The Hordaland Homocysteine Study. Am. J. Clin. Nutr. 71, 857-858 (2000).
70. Ulrich CM, Robien K, McLeod HL: Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer 3, 912-920 (2003).
71. Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW: Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum. Genet. 3, 299-302 (2002).
72. Evans WE, Relling MV, Rodman JD, Crom WR, Boyett JM, Pui CH: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338(8), 499-505 (1998).
73. Hills Rj, Ive FA: Folinic acid rescue used routinely in psoriatic patients with known methotrexate "sensitivity". Acta Derm. Venerol. 72, 438-440 (1992).
74. Jacman AL, Theti DS, Gibbs DD: Antifolates targeted specifically to the folate receptor. Adv. Drug Deliv. Rev. 56(8) 1111-1125 (2004).
75. Miklos GLG, Maleszka R: Microarray reality checks in the context of a complex disease. Nat. Biotech. 22(5), 615-621 (2004).